PapersFlow Research Brief
Telomeres, Telomerase, and Senescence
Research Guide
What is Telomeres, Telomerase, and Senescence?
Telomeres are protective DNA-protein structures at chromosome ends that shorten with cell divisions, telomerase is the enzyme that extends them, and senescence is the irreversible cell cycle arrest triggered by critically short telomeres, acting as a tumor suppression mechanism.
The field encompasses 46,722 papers on telomere dynamics, telomerase activity, and senescence mechanisms linked to tumor suppression, inflammation, and aging. Harley et al. (1990) demonstrated that telomeres shorten during ageing of human fibroblasts, establishing the molecular basis for replicative senescence limits observed by Hayflick (1965). Kim et al. (1994) showed specific association of human telomerase activity with 98 of 100 immortal cells and cancer samples, none in mortal populations.
Topic Hierarchy
Research Sub-Topics
Telomere Shortening and Replicative Senescence
This sub-topic examines the progressive shortening of telomeres with each cell division and its role in triggering replicative senescence, including mechanisms of end-replication problems and the Hayflick limit. Researchers study telomere length measurement techniques, attrition rates in human fibroblasts, and interventions to modulate shortening.
Telomerase Activity in Cancer and Immortality
This sub-topic investigates telomerase reverse transcriptase (TERT) expression, activation mechanisms, and its association with replicative immortality in cancer cells versus normal cells. Researchers explore telomerase inhibitors, promoter mutations, and diagnostic utility in oncology.
Oncogene-Induced Senescence
This sub-topic covers the premature senescence triggered by oncogenic signaling, such as RAS activation, involving p53 and p16INK4a pathways for tumor suppression. Researchers analyze senescence markers in response to oncogenes and evasion mechanisms in tumorigenesis.
Senescence-Associated Secretory Phenotype (SASP)
This sub-topic focuses on the proinflammatory secretome released by senescent cells, including cytokines, chemokines, and proteases, and its dual roles in tissue repair and pathology. Researchers study SASP regulation by NF-κB and therapeutic modulation.
Senolytics and Senescence Clearance
This sub-topic explores pharmacological agents that selectively eliminate senescent cells, their mechanisms targeting anti-apoptotic pathways like BCL-2, and efficacy in preclinical aging models. Researchers evaluate senolytic drug combinations and biomarkers of clearance.
Why It Matters
Telomere shortening and senescence suppress tumors by arresting proliferation in cells with DNA damage, as shown by Serrano et al. (1997) where oncogenic ras provoked premature senescence with p53 and p16INK4a accumulation. Bodnár et al. (1998) extended lifespan of normal human cells by introducing telomerase, bypassing senescence without malignant transformation, highlighting therapeutic potential for tissue engineering. Coppé et al. (2010) identified the senescence-associated secretory phenotype (SASP) that promotes inflammation and tissue dysfunction, contributing to age-related diseases like fibrosis and cancer progression in vivo.
Reading Guide
Where to Start
Start with 'The limited in vitro lifetime of human diploid cell strains' by Hayflick (1965) because it establishes the foundational observation of finite cell divisions, introducing the Hayflick limit central to understanding replicative senescence.
Key Papers Explained
Hayflick (1965) defined the finite divisions of human diploid cells; Harley et al. (1990) identified telomere shortening as the mechanism; Kim et al. (1994) linked telomerase to immortality. Bodnár et al. (1998) tested this by extending lifespan via telomerase in normal cells. Serrano et al. (1997) showed oncogene-induced senescence mimics replicative limits with p53/p16INK4a.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
López-Otín et al. (2023) in 'Hallmarks of aging: An expanding universe' updates the 2013 framework, integrating telomere attrition with new hallmarks like disabled macroautophagy and chronic inflammation. Coppé et al. (2010) details SASP's pathological roles, building on Campisi and d’Adda di Fagagna (2007).
Papers at a Glance
| # | Paper | Year | Venue | Citations | Open Access |
|---|---|---|---|---|---|
| 1 | The Hallmarks of Aging | 2013 | Cell | 14.2K | ✓ |
| 2 | A biomarker that identifies senescent human cells in culture a... | 1995 | Proceedings of the Nat... | 7.3K | ✓ |
| 3 | Specific Association of Human Telomerase Activity with Immorta... | 1994 | Science | 7.1K | ✕ |
| 4 | The limited in vitro lifetime of human diploid cell strains | 1965 | Experimental Cell Rese... | 5.8K | ✕ |
| 5 | Telomeres shorten during ageing of human fibroblasts | 1990 | Nature | 5.6K | ✕ |
| 6 | Oncogenic ras Provokes Premature Cell Senescence Associated wi... | 1997 | Cell | 5.0K | ✓ |
| 7 | Extension of Life-Span by Introduction of Telomerase into Norm... | 1998 | Science | 4.9K | ✕ |
| 8 | The Senescence-Associated Secretory Phenotype: The Dark Side o... | 2010 | Annual Review of Patho... | 4.8K | ✓ |
| 9 | Hallmarks of aging: An expanding universe | 2023 | Cell | 4.8K | ✕ |
| 10 | Cellular senescence: when bad things happen to good cells | 2007 | Nature Reviews Molecul... | 4.2K | ✕ |
Frequently Asked Questions
What is replicative senescence?
Replicative senescence is the irreversible growth arrest of normal somatic cells after a finite number of divisions, as described by Hayflick (1965) in 'The limited in vitro lifetime of human diploid cell strains'. Dimri et al. (1995) identified SA-β-gal as a biomarker for senescent human cells in culture and aging skin. This process acts as a tumor-suppressive mechanism triggered by telomere attrition.
How does telomerase relate to cancer?
Telomerase synthesizes DNA at chromosome ends, enabling indefinite proliferation, with Kim et al. (1994) finding activity in 98 of 100 immortal cell populations and cancer samples but none in 22 mortal ones. Harley et al. (1990) linked telomere shortening to senescence in aging fibroblasts. Bodnár et al. (1998) showed telomerase introduction extends normal cell lifespan without causing cancer.
What causes oncogene-induced senescence?
Oncogenic ras provokes premature senescence associated with p53 and p16INK4a accumulation, as demonstrated by Serrano et al. (1997). This arrests cells at risk of malignant transformation. It shares features with replicative senescence driven by telomere shortening.
What is the senescence-associated secretory phenotype?
SASP is a set of proinflammatory cytokines, chemokines, and proteases secreted by senescent cells that alter the tissue microenvironment, per Coppé et al. (2010). It reinforces senescence but can promote cancer and aging pathologies. Campisi and d’Adda di Fagagna (2007) noted SASP as a dark side of tumor suppression.
How do telomeres shorten with aging?
Telomeres shorten during aging of human fibroblasts due to incomplete replication, as shown by Harley et al. (1990). This acts as a mitotic clock triggering senescence after Hayflick limit. Telomerase absence in most somatic cells drives this progressive loss.
Open Research Questions
- ? How can SASP effects be selectively inhibited to mitigate aging-related inflammation without compromising tumor suppression?
- ? What precise telomere length thresholds trigger p53-dependent senescence pathways in vivo?
- ? Can telomerase activation in stem cells extend tissue renewal without oncogenic risk?
- ? How do senescent cells influence stem cell niches during organismal aging?
- ? What DNA damage response components mediate oncogene-induced senescence beyond p16INK4a and p53?
Recent Trends
López-Otín et al. published 'Hallmarks of aging: An expanding universe' with 4762 citations, expanding from the 2013 'The Hallmarks of Aging' (14200 citations) by adding hallmarks like microbiome disturbance and neuroinflammation tied to senescence.
2023The field holds 46,722 works with sustained focus on senolytics and DNA damage responses per keyword trends.
Research Telomeres, Telomerase, and Senescence with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Telomeres, Telomerase, and Senescence with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers